Salzberg Sacha P, Lachat Mario L, von Harbou Kai, Zünd Gregor, Turina Marko I
Department of Cardiovascular Surgery, University Hospital Zurich, Zurich, Switzerland.
Eur J Cardiothorac Surg. 2005 Feb;27(2):222-5. doi: 10.1016/j.ejcts.2004.11.001.
Pulmonary hypertension (PH) and elevated pulmonary vascular resistance (PVR) lead to poor outcome after heart transplantation due to postoperative failure of the non-conditioned right ventricle. The role of continuous flow left ventricular assist device (LVAD) support in the reduction of elevated PVR was evaluated in a series of clinical implants.
Among 17 patients with terminal heart failure receiving a MicroMed DeBakey LVAD as bridge to transplant, there were six patients with pulmonary hypertension (mean systolic PAP 47 mmHg) and high PVR (398 dynes/cm5), previously not considered suitable for heart transplantation, who underwent serial right heart catheters during their LVAD support period.
In these patients mean systolic pulmonary pressure dropped to 29 mmHg and PVR decreased to a mean 167 dynes/cm5 under LVAD support. Clinical improvement was significant in all patients. Four patients were successfully transplanted without major postoperative difficulties (mean duration 130 days support) and all are doing well to date. Post-transplant-PVR remained in the normal range in all transplanted patients.
Elevated PVR and severe PH were both previously considered as contraindication for heart transplantation. A period of LVAD pumping leads to a progressive decrease of PVR and normalization of pulmonary pressures, making these patients amenable for heart transplantation. LVAD as bridge to heart transplantation is safe and highly beneficial for terminal heart failure patients with severe PH.
肺动脉高压(PH)和肺血管阻力(PVR)升高会导致心脏移植术后因未适应的右心室功能衰竭而预后不良。本研究通过一系列临床植入病例评估了持续血流左心室辅助装置(LVAD)支持在降低升高的PVR中的作用。
在17例接受MicroMed DeBakey LVAD作为移植桥梁的终末期心力衰竭患者中,有6例肺动脉高压(平均收缩期肺动脉压47 mmHg)且PVR高(398达因/厘米⁵),此前被认为不适合心脏移植,在其LVAD支持期间接受了系列右心导管检查。
在这些患者中,LVAD支持下平均收缩期肺动脉压降至29 mmHg,PVR降至平均167达因/厘米⁵。所有患者临床均有显著改善。4例患者成功接受移植,术后无重大困难(平均支持时间130天),目前均情况良好。所有移植患者移植后的PVR均保持在正常范围内。
PVR升高和重度PH此前均被视为心脏移植的禁忌证。一段时间的LVAD辅助可使PVR逐渐降低,肺动脉压恢复正常,使这些患者适合心脏移植。LVAD作为心脏移植的桥梁对伴有重度PH的终末期心力衰竭患者安全且极为有益。